The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2024
Filed:
Mar. 28, 2018
Applicant:
The Regents of the University of Michigan, Ann Arbor, MI (US);
Inventors:
Shaomeng Wang, Superior Township, MI (US);
Haibin Zhou, Ann Arbor, MI (US);
Jianfeng Lu, Ann Arbor, MI (US);
Liu Liu, Ann Arbor, MI (US);
Yi Sun, Superior Township, MI (US);
Denzil Bernard, Ann Arbor, MI (US);
Assignee:
REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/454 (2006.01); A61K 31/5377 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01); C07D 277/30 (2006.01); C07D 277/64 (2006.01); C07D 417/12 (2006.01); C07K 5/02 (2006.01); C07K 5/062 (2006.01); C07K 5/078 (2006.01); C07K 5/097 (2006.01); C07K 5/113 (2006.01); C07K 5/117 (2006.01); C07K 7/02 (2006.01);
U.S. Cl.
CPC ...
C07K 5/1021 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/454 (2013.01); A61K 31/5377 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 38/07 (2013.01); A61K 45/06 (2013.01); C07D 277/30 (2013.01); C07D 277/64 (2013.01); C07D 417/12 (2013.01); C07K 5/02 (2013.01); C07K 5/021 (2013.01); C07K 5/06026 (2013.01); C07K 5/06139 (2013.01); C07K 5/0821 (2013.01); C07K 5/1024 (2013.01); C07K 7/02 (2013.01);
Abstract
Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.